Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine

Organic Cation Transporter OCTs (SLC22) and MATEs (SLC47) in the Human Kidney

(2013) Hideyuki Motohashi et al.   AAPS Journal

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole

(2013) Paul Martin et al.   Drugs in research & development

Intestinal drug transporters: An overview

(2012) Margarida Estudante et al.   ADVANCED DRUG DELIVERY REVIEWS

Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary

(2012) K. Thornton et al.   CLINICAL CANCER RESEARCH

Clinical Pharmacokinetics of Metformin

(2011) Garry G. Graham et al.   CLINICAL PHARMACOKINETICS

Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects

(2011) H Kusuhara et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics of Vandetanib: Three Phase I Studies in Healthy Subjects

(2011) Paul Martin et al.   CLINICAL THERAPEUTICS

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment

(2010) Angelika Weil et al.   CLINICAL PHARMACOKINETICS

OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine

(2010) Zhi-Jun Wang et al.   Pharmacogenetics and Genomics